Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its mRNA vaccine candidate RV-1770, targeting the respiratory syncytial virus (RSV) to prevent infections in adults.
The study will involve the administration of three different doses (50mg, 100mg, or 200mg) of the RV-1770 vaccine to healthy adults aged 18-49 and 60-79 through intramuscular injection. The trial aims to enroll 162 subjects, evenly divided into a young adult group and an elderly adult group, with 81 participants in each. Following vaccination, all subjects will be monitored for a period of 12 months to assess the safety and immunogenicity of RV-1770.- Flcube.com
